Targeted pill may shrink lung tumors before surgery in new trial

NCT ID NCT05740943

Ongoing Disease control Sponsor: Guangdong Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether taking the targeted drug lorlatinib for three months before surgery can shrink tumors in people with stage III ALK-positive non-small cell lung cancer. The study involves 48 participants and aims to see if the drug can eliminate all signs of cancer in the removed tissue. It also explores how genetic testing in the blood can help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib (a targeted cancer pill)
What this could lead to: If successful, this approach could shrink advanced lung tumors enough to allow surgery, potentially improving long-term control of the disease.
What could go wrong: This is a small, early-phase trial with only 48 participants. It is not yet proven to work better than standard treatment, and side effects from lorlatinib or surgery are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE III NSCLC SURGERY

Contacts and locations

Locations

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China
Guangzhou Twelfth People's Hospital

Guangzhou, Guangdong, China
Peking Union Medical College Hospital

Beijin, Beijin, 100730, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.